Fresenius Delivers First US Biosimilar Approval
Kabi Receives Long-Awaited Nod From FDA For Stimufend Version Of Pegfilgrastim
Executive Summary
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.
You may also be interested in...
Another US Humira Biosimilar Approved As Formularies Offer Access
As Fresenius Kabi receives US FDA approval for its Idacio rival to Humira, positive developments are being seen in terms of adding adalimumab biosimilars to local formularies. Meanwhile, in Europe Stada and Alvotech have broadened access to their Hukyndra high-concentration version.
Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation
Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.
Kabi’s Sen Succeeds Sturm As Fresenius Chief
Fresenius Kabi CEO Michael Sen is set to replace Fresenius group chief executive Stephan Sturm from the start of October. He will remain head of Kabi until a successor is appointed.